Laura Sutcliffe Analyst Performance

Laura Sutcliffe is a stock analyst at UBS Group in the medical sector, covering 6 publicly traded companies. Over the past year, Laura Sutcliffe has issued 2 stock ratings, including and buy recommendations. While full access to Laura Sutcliffe's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Laura Sutcliffe's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Analyst Ranking

Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeat

Average Return

00.00% 12-Month ROI

Success Rate

00.00% Profitable Ratings

Total Ratings

11 Last 9 Years

Buy Recommendations

81.82% 9 Buy Ratings

Companies Covered

6 Unique Companies

Ratings Distribution

Rating	Percentage	Count
Strong Buy	0.0%	0 ratings
Buy	81.8%	9 ratings
Hold	18.2%	2 ratings
Sell	0.0%	0 ratings

Out of 11 total stock ratings issued by Laura Sutcliffe at UBS Group, the majority (81.8%) have been Buy recommendations, followed by 18.2% Hold.

Best & Worst Calls

• Best Call

  00.0%

  GILD

  Sep 2016

  Subscribe to MarketBeat All Access to get analyst recommendation ROI.
• Worst Call

  000.0%

  BMY

  Jul 2016

  Subscribe to MarketBeat All Access to get analyst recommendation ROI.

Exchange Coverage

Exchange	Percentage	Count
NASDAQ	50.0% of companies on NASDAQ	3 companies
NYSE	33.3% of companies on NYSE	2 companies
OTCMKTS	16.7% of companies on OTCMKTS	1 company

Laura Sutcliffe, an analyst at UBS Group, currently covers 6 companies listed on NASDAQ, NYSE and OTCMKTS, with the majority traded on NASDAQ.

Coverage Focus

Sector Icon	Sector	Percentage
	Medical 6 companies	100.0%

Laura Sutcliffe of UBS Group specializes in stock coverage within the Medical sector.

Coverage Industries

Industry	Percentage
MED - BIOMED/GENE 4 companies	66.7%
MED PRODUCTS 1 company	16.7%
PHARMACEUTICAL PREPARATIONS 1 company	16.7%

Laura Sutcliffe's Ratings History at UBS Group

Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe

Start Date

End Date

All Ratings Strong Buy Buy Hold Sell Rating

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription

12-Month ROIUpgrade to All Access to use the All ROI Filter

Export to Excel

Company	Report Date	Action	Report Date Price	12-Month Price Target	Rating	12-Month Price & ROI	Details
RMD ResMed	8/1/2025	Boost Price Target	$279.57	$325.00	Buy	$0.00 00.00% ROI
TLX Telix Pharmaceuticals	1/27/2025	Boost Price Target	$18.60	$22.00	Buy	$0.00 00.00% ROI

Stock Forecasts and Research Tools

Sign in to your free account to enjoy these benefits

• In-depth profiles and analysis for 20,000 public companies.
• Real-time analyst ratings, insider transactions, earnings data, and more.
• Our daily ratings and market update email newsletter.

Sign in to your free account to enjoy all that MarketBeat has to offer.

• Sign In
• Create Account

Your Email Address:

Email Address Required

Your Password:

Password Required

Log In

---

or

Sign in with Facebook Sign in with Google

Forgot your password?

Your Email Address:

Please enter your email address.

Please enter a valid email address

Choose a Password:

Please enter your password.

Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character.

Create My Account (Free)

---

or

Sign in with Facebook Sign in with Google

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.